AbCellera Biologics Inc. (ABCL)

AbCellera Biologics Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Jun 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Net Income	-165.67	-162.86	-146.4	158.52	153.46	118.92
Depreciation & Amortization	33.86	65	30.89	24.7	17.25	5.27
Asset Writedown & Restructuring Costs	32	32	-	8.4	-	-
Stock-Based Compensation	61.38	67.58	64.18	49.48	30.65	8.4
Other Operating Activities	-45.25	-84.44	-5.78	6.43	1.55	6.81
Change in Accounts Receivable	-53.21	-75.12	-36.66	106.46	22.48	-203.02
Change in Accounts Payable	3.41	10.64	-15.1	-2.09	-3.24	6.6
Change in Unearned Revenue	26.74	26.04	25.55	15.45	39.34	15.05
Change in Income Taxes	5.02	6.65	30.46	-88.61	-13.53	36.41
Change in Other Net Operating Assets	20.88	5.95	8.98	-1.38	-3.38	28.26
Operating Cash Flow	-80.84	-108.56	-43.88	277.36	244.58	22.69
Operating Cash Flow Growth	-	-	-	13.40%	977.94%	742.24%
Capital Expenditures	-58.15	-78.4	-76.95	-70.66	-58.45	-9.67
Cash Acquisitions	-	-	-	-	-11.46	-87.64
Sale (Purchase) of Intangibles	-	-	-0.56	-2	-	-5
Investment in Securities	51.27	164.1	-168.91	-296.4	-294.96	-17.46
Other Investing Activities	22.41	35.71	25.31	16.43	32.62	-
Investing Cash Flow	15.53	121.41	-221.11	-352.63	-332.25	-119.78
Long-Term Debt Issued	-	13.5	11.59	2.76	5.49	89.99
Total Debt Issued	19.3	13.5	11.59	2.76	5.49	89.99
Long-Term Debt Repaid	-	-	-	-	-	-19.94
Total Debt Repaid	-	-	-	-	-	-19.94
Net Debt Issued (Repaid)	19.3	13.5	11.59	2.76	5.49	70.05
Issuance of Common Stock	-	-	-	-	-	539.33
Other Financing Activities	-9.42	-0.73	-1.23	-4.38	-9.37	-0.39
Financing Cash Flow	9.88	12.77	10.36	-1.63	-3.89	683.65
Foreign Exchange Rate Adjustments	-0.44	-2.62	0.59	-9.6	-1.43	-
Net Cash Flow	-55.88	23.01	-254.04	-86.49	-92.97	586.56
Free Cash Flow	-138.99	-186.95	-120.82	206.7	186.13	13.02
Free Cash Flow Growth	-	-	-	11.05%	1329.91%	-
Free Cash Flow Margin	-422.76%	-648.40%	-317.75%	42.58%	49.61%	5.58%
Free Cash Flow Per Share	-0.47	-0.64	-0.42	0.66	0.58	0.05
Levered Free Cash Flow	-207.59	-177.77	-102.96	205.62	143.8	-24.06
Unlevered Free Cash Flow	-207.59	-177.77	-102.96	205.62	143.8	-19.8
Change in Working Capital	2.83	-25.84	13.23	29.83	41.67	-116.7

Updated Jun 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q